
Ochre Bio
Ochre Bio is a YC Winter 2020 (W20) company. Based in Oxford, England, United Kingdom. Team of 50.
About Ochre Bio
Summary
Ochre Bio develops RNA medicines for chronic liver diseases, conditions that currently have few effective treatment options. The company combines AI with human liver data and human tissue models to discover and validate disease pathways, replacing the reliance on animal models and less disease-specific datasets that have historically limited liver drug development.
Go-to-market
Ochre Bio works with large pharmaceutical companies, including GSK, Boehringer Ingelheim, and Takeda, which access its proprietary human liver datasets and AI-generated disease models through research partnerships as a path toward co-developing novel liver therapeutics.
From the Y Combinator listing
RNA medicines for liver diseases
Ochre Bio is a biotechnology company developing RNA medicines for chronic liver diseases.
Facts
- Healthcare / Healthcare -> Therapeutics
- Oxford, England, United Kingdom
- 50
- Active
- Growth
Founders (1)
- Quin Wills
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works